The company’s latest financial report highlights a successful transition into a period of high-quality growth and sustained profitability. IFRS net profit reached RMB 1.3 billion, a 50% year-over-year increase, supported by a robust cash reserve of RMB 30.2 billion. This financial stability provides the foundation for the firm’s 2030 vision, which targets revenue between RMB 35 billion and 40 billion while aiming for top-tier profit margins comparable to global pharmaceutical giants.
In section Releases
Innovent Biologics Charts Path to Global Premier Status by 2030
Innovent Biologics has reported a significant surge in its 2026 interim results, with total revenue climbing 45% to RMB 8.6 billion. As the company shifts from a regional Chinese leader to an international biopharma player, it is leveraging a dual-engine strategy in oncology and metabolic disease to fuel global expansion.
Innovent is accelerating its international footprint through strategic collaborations, including high-profile partnerships with Takeda, Eli Lilly, and Pfizer. The company currently manages over 20 pipeline assets with an aggregate deal value of USD 34 billion. Key late-stage assets, such as the PD-1/IL-2 biased candidate IBI363 and the CLDN18.2 ADC IBI343, are positioned to capture a combined addressable market exceeding USD 60 billion. With successful GMP inspections by the European Medicines Agency, Innovent is scaling its 140,000-liter manufacturing capacity to meet the demands of both domestic and overseas markets.
Comments (0)
No comments yet. Be the first!